One cheap stock worth considering is drugmaker Viatris (NASDAQ:VTRS). It trades at a ridiculously low price-to-earnings ratio of 4.2 and recently announced its first quarterly results and dividend payment. Viatris looks incredibly attractive at these levels, and its business is beginning to show signs of stability.
Is Viatris going to pay a dividend?
A cash dividend payment of $0.11 per share is scheduled to be paid on June 16, 2021. Shareholders who purchased VTRS prior to the ex-dividend date are eligible for the cash dividend payment. At the current stock price of $15.5, the dividend yield is 2.84%.
Can I buy Viatris shares?
Viatris Inc., formerly Up Upjohn Inc., is a healthcare company. It is a scientific, manufacturing and distribution company that is specialized in delivering medicines to patients in over 165 countries and territories. , you can buy Viatris Inc stock in any dollar amount, or any other fund or stock you know on Stash.
What kind of company is Viatris?
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn on November 16, 2020.
|Founded||November 16, 2020|
Is Viatris a Pfizer company?
Viatris was formed as a result of the spin-off by Pfizer Inc. (“Pfizer”) of its global, primarily off-patent branded and generic established medicines business (the “Upjohn Business”) and, immediately thereafter, the combination of the Upjohn Business with Mylan N.V. (“Mylan”).
Is Pfizer a good stock to buy right now?
Pfizer also currently offers a dividend yield of 3.84%, almost triple what the SPDR S&P 500 ETF offers at just 1.34%. A cheap stock price with lots of potential to rise, and a dividend yield well above average, is a combination that should make investors very optimistic about Pfizer stock in 2021.
What stocks pay good dividends?
List of 25 high-dividend stocks
|Symbol||Company Name||Dividend Yield|
|LYB||LyondellBasell Industries NV||4.39%|
|GILD||Gilead Sciences Inc.||4.12%|
Is Viatris a buy or sell?
Currently, Viatris trades at a forward P/E of just 4.2, making it one of the cheapest stocks on the market today. The consensus among analysts on Wall Street is that the stock will rise by 50% over the next year.
Will VTRS stock go up?
Based on our forecasts, a long-term increase is expected, the “VTRS” stock price prognosis for 2026-07-06 is 19.441 USD. With a 5-year investment, the revenue is expected to be around +35.86%. Your current $100 investment may be up to $135.86 in 2026.
Is VTRS a buy or sell?
Out of 7 analysts, 0 (0%) are recommending VTRS as a Strong Buy, 1 (14.29%) are recommending VTRS as a Buy, 6 (85.71%) are recommending VTRS as a Hold, 0 (0%) are recommending VTRS as a Sell, and 0 (0%) are recommending VTRS as a Strong Sell. What is VTRS’s earnings growth forecast for 2021-2023?
Why did I get shares of VTRS?
A lot of people who own Viatris (NASDAQ:VTRS) stock didn’t even buy it. That’s because Viatris was formed through the merger of Mylan and Upjohn, the generics unit of Pfizer (NYSE:PFE). Pfizer shareholders were given a little more than 12 shares in Viatris for every 100 they held in Pfizer.
What happened to MYL?
Some 16 months after the deal was announced, generic drugmaker Mylan officially combined with Pfizer Inc.’s Upjohn unit Monday to form a new company called Viatris.
Why is Pfizer stock low?
One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it’s really just weighed on their revenue growth, earnings growth, and that’s been a big problem.
Why is Mylan stock so low?
Mylan Stock Is Falling Because the Upjohn Deal Won’t Soon Help Earnings, Analyst Says. One of the biggest questions for biopharma investors in 2020 is what to make of the big new generic-drug company being formed by the merger Mylan with Pfizer’s off-patent drug division.
What companies has Pfizer bought?
In June 2015, the company acquired Nimenrix and Mencevax, meningococcal vaccines, from GlaxoSmithKline for around $130 million. In September 2015, Pfizer acquired Hospira for $17 billion, including the assumption of debt. Hospira was the largest producer of generic injectable pharmaceuticals in the world.
Will Pfizer spin off Upjohn?
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. … Under the terms of the transaction, which was structured as an all-stock Reverse Morris Trust, Upjohn Inc.